S100A9 and COVID-19: In HSPCs of COVID-19, late-phase CD14+ monocytes retain elevated levels of inflammatory mediators such as S100A8 and S100A9 relative to both healthy controls and early-phase samples, underscoring their progression toward a more differentiated, pro-inflammatory phenotype (40).